GenFleet Therapeutics, a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology worldwide, today announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for GFH925 in a multi-center phase I / II clinical trial treating advanced solid tumors among patients with KRAS G12C gene mutation.
The agreement outlines a constructive framework where GenFleet will synergize its own R&D systems with Insilco’s end-to-end AI-powered drug discovery platform and Biortus’ structural biology platform, with a view to jointly addressing significant unmet medical needs and tackling novel & difficult targets in cancer therapeutics.
May 10，2021 (Tianjin, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced that the first patient has been dosed in its first-in-human trial of GFH009.
April 27, 2021 (Melbourne, Australia) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced its first-in-human phase I trial of GFH312 has achieved dosing of subjects in the first cohort.
January 27, 2021 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology
December 21, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company developing first-in-class therapies in oncology and immunology worldwide
November 2, 2020 (Shanghai, China) - GenFleet Therapeutics, a clinical-stage biotechnology company focusing first-in-class therapies in oncology and immunology
March 8, 2020 (Shanghai, China) -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on first-in-class therapies in oncology and immunology
